{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:48:24Z","timestamp":1782960504945,"version":"3.54.5"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,1,5]],"date-time":"2002-01-05T00:00:00Z","timestamp":1010188800000},"content-version":"vor","delay-in-days":1222,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[1998,9]]},"abstract":"<jats:sec><jats:label\/><jats:p>Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S (University Hospital, Groningen; Free University Hospital, Amsterdam; and Catharina Hospital, Eindhoven; the Netherlands). Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with antiproteinase 3 and antimyeloperoxidase autoantibodies. <jats:italic>J Intern Med<\/jats:italic> 1998; <jats:bold>244<\/jats:bold>: 209\u201316.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the disease spectrum of consecutive patients with antineutrophil cytoplasmic autoantibodies directed against proteinase 3 (anti\u2010PR3) or myeloperoxidase (anti\u2010MPO).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Three teaching hospitals in the Netherlands.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Clinical features at presentation, histopathological characteristics and outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects<\/jats:title><jats:p>All consecutive patients who tested positive for anti\u2010PR3 (<jats:italic>n<\/jats:italic>= 46) or anti\u2010MPO (<jats:italic>n<\/jats:italic>= 46) over an 8\u2010year\u2010period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At diagnosis, patients with anti\u2010PR3 had a higher vasculitis activity index than patients with anti\u2010MPO (<jats:italic>P<\/jats:italic> &lt; 0.001). The mean (SD) number of affected organs in the anti\u2010PR3 group exceeded that of the anti\u2010MPO group (3.9 (1.4) and 2.2 (1.1), respectively; <jats:italic>P<\/jats:italic> &lt; 0.01). The combination of renal and respiratory tract involvement was present in as many as 78.3% of patients with anti\u2010PR3 and in only 23.9% of patients with anti\u2010MPO (P &lt; 0.01). Renal\u2010limited disease exclusively occurred in patients with anti\u2010MPO. Granulomas were found in 41.3% of anti\u2010PR3\u2010 but in only 4.3% of anti\u2010MPO\u2010positive patients (<jats:italic>P<\/jats:italic> &lt; 0.01). All anti\u2010PR3\u2010positive patients had Wegener's granulomatosis or microscopic polyangiitis. By contrast, diagnoses in the anti\u2010MPO group were more diverse: idiopathic necrotizing crescentic glomerulonephritis (26.1%), microscopic polyangiitis (26.1%), Churg\u2013Strauss syndrome (4.3%), Wegener's granulomatosis (2.2%), giant cell arteritis (2.2%), clinically suspected vasculitis (19.6%), as well as miscellaneous nonvasculitic disorders (19.6%). During follow\u2010up, 10 anti\u2010PR3\u2010positive patients had 11 relapses whereas only 3 patients with anti\u2010MPO relapsed (<jats:italic>P<\/jats:italic>= 0.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A large divergence was seen in the disease spectrum between patients with anti\u2010PR3 and those with anti\u2010MPO. In particular, extra\u2010renal disease manifestations, granuloma formation and relapses were more prominent in anti\u2010PR3\u2010 than in anti\u2010MPO\u2010positive patients.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2796.1998.00357.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T06:07:46Z","timestamp":1047449266000},"page":"209-216","source":"Crossref","is-referenced-by-count":107,"title":["Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti\u2010proteinase 3 and anti\u2010myeloperoxidase autoantibodies"],"prefix":"10.1111","volume":"244","author":[{"family":"Franssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kallenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hageluken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hoorntje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-9-656"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.239"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91507-3"},{"key":"e_1_2_6_5_2","first-page":"107","article-title":"The new ACPA\/ANCA nomenclature.","volume":"36","author":"Wiik A","year":"1990","journal-title":"Neth J Med"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)65775-9"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114335"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V75.11.2263.2263","article-title":"Specificity of anti\u2010neutrophil cytoplasmic autoantibodies for proteinase 3.","volume":"78","author":"Jennette JC","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_9_2","first-page":"558","article-title":"Autoantibodies against myeloid lysosomal enzymes: a novel class of autoantibodies associated with vasculitic syndromes.","volume":"34","author":"Goldschmeding R","year":"1988","journal-title":"Kidney Int"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806233182504"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1992.tb05835.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1980.tb01768.x"},{"key":"e_1_2_6_13_2","first-page":"161","article-title":"Immunodiagnostic aspects of autoantibodies against myeloperoxidase.","volume":"37","author":"Ulmer M","year":"1992","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61782-0"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb03345.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-1-28"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/archinte.1989.00390110055012","article-title":"Association between active Wegener's granulomatosis and anticytoplasmic antibodies.","volume":"149","author":"Cohen Tervaert JW","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_18_2","first-page":"270","article-title":"Anti\u2010neutrophil cytoplasmic autoantibodies and Wegener's granulomatosis (letter).","author":"Cohen Tervaert JW","year":"1989","journal-title":"Lancet"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330829"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1990.48"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1991.tb00342.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91761-A"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80521-X"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91273-7"},{"key":"e_1_2_6_25_2","first-page":"9","article-title":"Disease associations and pathogenic role of antineutrophil cytoplasmic autoantibodies in vasculitis.","volume":"4","author":"Jennette JC","year":"1992","journal-title":"Curr Opin Rheumatol"},{"key":"e_1_2_6_26_2","first-page":"921","article-title":"Anti\u2010neutrophil cytoplasmic autoantibody\u2010associated glomerulonephritis and vasculitis.","volume":"135","author":"Jennette JC","year":"1989","journal-title":"Am J Pathol"},{"key":"e_1_2_6_27_2","first-page":"12","article-title":"Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.","volume":"97","author":"Wiik A","year":"1989","journal-title":"APMIS"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb05577.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90074-8"},{"key":"e_1_2_6_30_2","first-page":"671","article-title":"Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis.","volume":"87","author":"Luqmani RA","year":"1994","journal-title":"Quart J Med"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92205-V"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370206"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000166586"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.23"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.285.6342.606"},{"key":"e_1_2_6_36_2","first-page":"125","article-title":"Clinical spectrum associated with ANCA of defined specificities in 98 selected patients.","volume":"39","author":"Geffriaud\u2010Ricouard C","year":"1993","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_37_2","first-page":"114","article-title":"Different immunological specificities and disease associations of c\u2010ANCA and p\u2010ANCA.","volume":"36","author":"Goldschmeding R","year":"1990","journal-title":"Neth J Med"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90202-M"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-98-1-76"},{"key":"e_1_2_6_40_2","first-page":"135","article-title":"Pathogenic potential of anti\u2010neutrophil cytoplasmic autoantibodies.","volume":"70","author":"Jennette JC","year":"1994","journal-title":"Lab Invest"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb05511.x"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2796.1998.00357.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2796.1998.00357.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2796.1998.00357.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2796.1998.00357.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:50:33Z","timestamp":1694418633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2796.1998.00357.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,9]]}},"alternative-id":["10.1046\/j.1365-2796.1998.00357.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2796.1998.00357.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,9]]}}}